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Abstract
PIWI-interacting RNAs (piRNAs) are emerging players in cancer genomics. Originally described in the germline, there
are over 20,000 piRNA genes in the human genome. In contrast to microRNAs, piRNAs interact with PIWI proteins,
another member of the Argonaute family, and function primarily in the nucleus. There, they are involved in the
epigenetic silencing of transposable elements in addition to the transcriptional regulation of genes. It has recently
been demonstrated that piRNAs are also expressed across a variety of human somatic tissue types in a tissue-specific
manner. An increasing number of studies have shown that aberrant piRNA expression is a signature feature
across multiple tumour types; however, their specific tumorigenic functions remain unclear. In this article, we
discuss the emerging functional roles of piRNAs in a variety of cancers, and highlight their potential clinical
utilities.
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Background
With the realization that less than 3 % of the transcribed
human genome is translated into protein, there has been a
surge of interest in the role of the non-coding RNA tran-
scriptome and its contribution to pathogenesis [1–4].
Among the types of human non-coding RNAs, micro-
RNAs (miRNAs) and long non-coding RNAs (lncRNAs)
have been extensively studied in cancer [5–21] (Fig. 1). P-
element-induced wimpy testis (PIWI)-interacting RNAs
(piRNAs) are a class of small non-coding RNA molecules
that have been recently recognized to be relevant to can-
cer biology. Today, conservative estimates for the total
number of piRNAs in the eukaryotic genome parallel
those of protein-coding genes (~20,000), and largely ex-
ceeds the estimated 2,000 miRNA loci present [22, 23].
Initially termed “repeat associated small interfering RNAs”
(rasiRNAs) [24], they were designated piRNAs for their
interaction with the PIWI subfamily of Argonaute pro-
teins [25, 26]. PIWI proteins have been extensively ex-
plored in germline and stem cells, and have the unique
ability of binding 2′-O-methylated RNAs -a distinguishing
feature of piRNAs- at their 3′ end [27–29].
The piRNA/PIWI interaction is an example of the highly
conserved small RNA-guided mechanism of gene regula-
tion, which involves interaction between a sequence-
recognition RNA and a member of the Argonaute protein
family [30]. The specific mechanism by which regulation
occurs is dependent on the type of small RNA. Small inter-
fering RNAs (siRNAs) and miRNA interact with the Ago
subfamily of Argonaute family, whereas piRNAs interact
with PIWI proteins [31, 32]. Furthermore, unlike siRNA
and miRNA, the piRNA/PIWI complex has been primarily
described as functioning through epigenetic silencing ra-
ther than transcript targeting [33].
PIWI was first discovered in Drosophila melanoga-
ster in relation to germline stem cell self-renewal;
therefore, much of the focus has been on the piRNA/
PIWI complex’s role in the germline [34]. Germline
piRNAs are primarily involved in the silencing of self-
ish genetic elements, including transposable elements
(TEs) [26]. In addition to their well-known epigenetic
functions [33, 35], recent studies in Drosophila and
mice suggest that piRNAs may additionally regulate* Correspondence: vmartinez@bccrc.ca
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gene expression through a miRNA-like transcript si-
lencing mechanism in the cytoplasm [36–38].
In this review, we discuss what is known about piR-
NAs in germline cells, and their emerging roles in
somatic and cancerous tissues. Furthermore, we dis-
cuss the diagnostic and prognostic potential utility of
piRNAs.
The piRNA/PIWI protein interaction in germline
and somatic tissues
piRNAs accomplish their regulatory function through
binding to PIWI proteins from the Argonaute family,
resulting in the formation of a silencing ribonucleopro-
tein complex that can recognize and silence comple-
mentary sequences [39, 40]. The most well-established
function of this complex is the maintenance of genome
integrity through TE silencing in the germline at both
the transcriptional and post-transcriptional level, which
is linked to its biogenesis and is a conserved function
among different animal species [41, 42] (Fig. 2). How-
ever, it has also been suggested that piRNAs have spe-
cific functions in both the germline and somatic tissues
of various organisms, including conserved mammalian
biological functions [43].
piRNA function in germline tissue
Repression of transposable elements
TEs can contribute to genetic diversity as well as genetic
instability [44, 45]. This can result in pathogenesis through
gene deregulation, chromosome rearrangement, and dele-
terious mutation, and has been linked to a number of can-
cers [46, 47]. In particular, the role of non-long terminal
repeat (non-LTR) TEs, including long interspersed ele-
ments (LINEs) and short interspersed elements (SINEs)
has been implicated, with particular emphasis on non-LTR
families L1, SVA, and Alu in leukemia, breast, ovarian, and
colon cancers [48]. In particular, somatic L1 insertions have
been found to occur in and disrupt the expression of com-
monly mutated genes in cancer [47]. This enhanced L1 in-
sertion has also been demonstrated in vitro in a variety of
cancer cell lines, which additionally display increased RNA
polymerase II binding to TEs compared to non-malignant
cell lines [49].
The PIWI protein localizes to the nucleus and works
at the transcriptional level, establishing a repressive
chromatin state as the result of an increase in H3K9me3
and HP1 chromatin marks (Fig. 2b) [41]. Overexpression
of piRNA has been associated with the recruitment of
PIWI, HP1a, and Su(var)3–9, the reduction of RNAPII,
Fig. 1 Selected types of small and long non-coding RNAs. Non-coding RNAs show diversity in size and function. The small non-coding RNA category
(20–35 bp) includes: microRNAs (miRNAs), tRNA-derived fragment (tRF), PIWI-interacting RNAs (piRNAs), C/D snoRNA-derived RNA (sdRNAs), and small
interfering RNAs (siRNAs). The long non-coding RNA category (>200 bp) includes promoter associated long RNAs (PARs), transcribed ultraconserved
regions (T-UCR), long non-coding RNAs (lncRNAs), pseudogenes, and antisense RNAs (asRNAs). piRNAs (red line) are larger than other small RNAs and,
unlike most of the other small RNA (with the exception of snoRNA), are functionally active both the nucleous and the cytoplasm
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and the enrichment of H3K9me2/3 [33]. Indeed, piRNA-
mediated epigenetic silencing of TEs in Drosophila has
been shown to result in the silencing of adjacent genes
as well [50]. In Drosophila, it has been shown that the
PIWI proteins Aubergine (Aub) and Argonaute 3 (Ago3)
localize to the cytoplasm and repress transposons at a
post-transcriptional level through the cleavage of tran-
scripts (Fig. 2b) [36, 51]. The coexistence of both cyto-
plasmic and nuclear piRNAs further supports this theory
[37]. Additionally, it has been reported that Ago3-
mediated RNA cleavage drives the production of anti-
sense piRNAs that direct transcriptional silencing by
Piwi in Drosophila [52].
piRNA/PIWI-mediated regulation of TEs has also
been well characterized in mammals. Mice exhibit the
expression of three PIWI-like proteins: Miwi, Mili, and
Miwi2 [53]. Miwi2 possesses many similarities to the
PIWI protein present in Drosophila [54] and it has been
suggested that both Mili and Miwi2 affect the methyla-
tion status of repetitive elements in order to maintain
the stable repression of transposons [54, 55]. In mice,
specific piRNA knockdown leads to the derepression of
LINE-1 [53]. As well, a decrease in piRNA cluster ex-
pression has been shown to be associated with increased
TE activity [53]. A study of pig testes suggests that a con-
served and dynamic mammalian piRNA/PIWI system plays
a critical role in post-transcriptional gene regulation [43]. A
similar finding occurred in marmoset testes tissue, where
small RNA profiling revealed that piRNA clusters may
use pseudogene-derived piRNAs to regulate protein-
coding genes based on the strand-bias of TE-derived
piRNAs [56]. This finding further supports a conserved
mammalian piRNA system.
Epigenetic activation
In addition to a role in TE activity, piRNAs have also been
shown to play a role in the epigenetic activation of gene
expression. PIWI protein complexes have been shown to
promote euchromatic histone modifications and the tran-
scription of piRNAs [35]. Specifically, PIWI has been
shown to have a positive regulatory role in the expression
of the 3R-TAS1 piRNA in germline stem cells of Drosoph-
ila melanogaster. The absence of PIWI has been shown to
exert opposite genomic regulatory effects on different
parts of the gene, namely resulting in enhanced telomere
position effects in the white eye gene in Drosophila. Thus,
since PIWI is required for the expression of this reporter
gene in a dose-dependent manner, it is shown to promote
Fig. 2 Biogenesis and functions of the piRNA/PIWI complex. piRNA and PIWI proteins form a ribonucleoprotein complex that is primarily
responsible for the maintenance of genome integrity through transposable element (TE) silencing in the germline at both the transcriptional
and post-transcriptional level. a The ribonucleoprotein complex is active in piRNA biogenesis, where it cleaves target RNAs at the position 10
and 11 of the guide strand, generating the 5′ end of the cleavage product that will be loaded to a second PIWI protein, and gives rise to a
secondary piRNA, after nucleolytic processing of the 3′ end. Primary piRNAs have uridine (U) bias at their 5′ nucleic acid, while secondary
piRNAs, which shows 10 nucleotide complementarity with primary piRNAs at their 5′ ends, exhibits a bias for adenosine (A) at the tenth
nucleotide. b In the nucleus, the complex is active in epigenetic silencing, through the establishment of a repressive chromatin state as a
result of the recruitment of Heterochromatin protein 1 (HP1a) and histone methyltransferases (HMT); and epigenetic activation, through
euchromatic histone modifications that allows binding of proteins such as JmjC domain-containing histone demethylation protein 1 (Epe1),
chromodomain protein1 and 2 (Chp1, Chp2) and Chromatin-associated protein Swi6. In the cytoplasm, it is active in mRNA degradation through
association with the carbon catabolite repressed 4 - negative on TATA-less (CCR4–NOT) deadenylation complex, together with Smaug (Smg)
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the active epigenetic state of 3R-TAS [35]. Additionally, in
Caenorhabditis elegans, the piRNA and Argonaute protein
CSR-1 complex has been shown to cause additional re-
cruitment of histone modifying enzymes, which result in
epigenetic activation [57].
mRNA decay
In murine spermatogenesis, piRNAs play key silencing
roles beyond TE repression. Following the first wave of
TE-derived piRNA production, a second wave of piRNA
has been observed to target transcripts in late stages of
spermatogenesis [58]. Through the recruitment of Miwi
and deadenylase CAF1, a piRNA-induced silencing com-
plex is assembled and induces mRNA deadenylation and
degradation [58]. This miRNA-like mechanism has been
shown to be dependent on the physical association of
Miwi with piRNA target sites on mRNA [59].
piRNA expression and functions in somatic tissue
Although most attention has been given to the func-
tional role of piRNAs in germline TE regulation, increas-
ing evidence has pointed to piRNA function not only
beyond TE regulation, but also outside germline cells.
Studies in Drosophila and mammals suggest a role in gene
regulation performed by piRNAs derived from protein-
coding genes [43]. Colocalization of piRNAs encoded by
mitochondrial DNA and PIWI proteins in mammalian
somatic cell lines suggests they may function as part of
the stress response [60]. Additionally, the Smg-CCR4-
NOT-Aub-dependent mechanism of mRNA deadenyla-
tion and decay has also been demonstrated to occur in the
soma in Drosophila [51, 61].
Consistent with emerging roles for piRNAs in the
cytoplasm as well as in the nucleus, piRNA-like-163
(piR-L-163) was observed to localize to both the cyto-
plasm and nucleus of human bronchial epithelial cells
(HBECs) at various points throughout the cell cycle [62].
Analysis of piR-L-163-interacting proteins through li-
quid chromatography-mass spectrometry (LC-MS) im-
plicated the ERM (Ezrin/Radixin/Moesin) family of
proteins. Strikingly, piR-L-163 appeared to bind exclu-
sively to activated phosphorylated ERM proteins and not
to inactive forms, and was also demonstrated to be crit-
ical for ERM’s biological function [62].
Though exploration of piRNA expression in humans
has focused mainly on germline tissue, it has recently been
noted that piRNA are expressed across human somatic
tissue. In human adult testes, expressed piRNAs are
enriched in 3′ untranslated regions UTRs, as compared to
coding DNA sequences (CDSs) and 5′UTRs [63]. Add-
itionally, it has been shown that the number of piRNAs
expressed in somatic tissue is considerably lower than that
observed in germline tissues, although there is tissue spe-
cificity associated with the expressed piRNAs [64].
piRNA expression in humans: novel functions and
role in cancer
Functional roles of piRNAs in cancer
As piRNAs are implicated in gene regulation and silen-
cing, there has been a budding interest in defining the
role of piRNAs in human disease [65]. In particular,
interest in the piRNA field has focused on human can-
cers, as demonstrated in a recent surge of publications
(Fig. 3). In conjunction with this, the role of PIWI pro-
teins themselves in cancer has been extensively studied
[66], further underscoring the role of the piRNA/PIWI
complex in tumorigenesis.
Additionally, over or underexpression of piRNAs that tar-
get mRNA transcripts (e.g. those containing transposon-
derived sequences in their 3′UTRs) could also play a driver
role through degradation or inhibition of tumour suppres-
sor genes or oncogenes, respectively [37]. On the other
hand, the disruption of piRNAs that normally suppress TE
activity may facilitate mutagenic retrotranspositions and
genomic instability, thereby contributing to tumorigenesis;
however, this does not appear to be the case as ectopic ex-
pression of piRNA/PIWI tends to result in a more aggres-
sive cancer phenotype [67].
Epigenetic modifications, such as DNA hypo/hyperme-
thylation and histone modifications, are hallmarks of the
development and progression of cancer [68]. Remark-
ably, the recent functional evidence concerning the role
Fig. 3 Number of piRNA-related publications per year. Search was
performed within EndNote (version 7, Thomson Reuters) and manually
filtered. Number of entries are based on a United States National
Library of Medicine (NLM) PubMed search using the terms “piRNA
OR PIWI-interacting RNA” (blue line) or “piRNA OR PIWI-interacting
RNA AND cancer” (red line) and annual (Jan 1-Dec 31) date limitations.
2015 publications were not included in the search
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of piRNAs in tumorigenesis points to the involvement of
these small RNAs in the regulation of epigenetic mecha-
nisms, coupled with the acquisition of cancer-like phe-
notypes in human models. It has been proposed that the
piRNA/PIWI may contribute to tumorigenesis through
aberrant DNA methylation resulting in genomic silen-
cing and promotion of a “stem-like” state [69]. More
specifically, piRNAs are able to induce DNA methylation
changes in genomic regions close to their binding sites.
In human lymphoma and breast cancer cell lines, single-
copy piRNAs mediate gene-specific DNA methylation
through imperfect binding to genomic DNA near target
CpGs at non-TE sites [70]. Additionally, breast cancer
cell lines transfected with a variant of piR-021285 con-
taining the rs1326306 SNP showed reduced methylation
at a CpG site within the 5′ UTR/first exon of ARH-
GAP11A gene, resulting in increased gene expression
and augmented migration capability in cell lines com-
pared to those carrying the WT form of this piRNA [71].
piRNAs can also activate the gene expression by inducing
euchromatin state through upregulation of H3K4me3 and
inhibition of H3K27me3 in subtelomeric heterochromatin
regions in Drosophila [35]. Consistent with this mechanism,
piRNA-like molecules located in intronic regions of the
Growth Arrest Specific 5 (GAS5) gene, together with
PIWIL1/4, are able to recruit a hCOMPASS-like complex
to the promoter region of the Tumor Necrosis Factor (Lig-
and) Superfamily, Member 10 (TRAIL) tumor suppressor
gene. This, together with induction of H3K4 methylation
and H3K27 demethylation, resulted in transcriptional acti-
vation of TRAIL and consequently, inhibition of tumor
growth [72].
piRNAs have been also linked to other possible tumori-
genic, non-epigenetic functions in cells, such as cell cycle
regulation. Depletion of the piRNA piR-L-163 resulted in
accelerated DNA synthesis and G2-M accumulation, to-
gether with increased invasion and cell migration capabil-
ities in human bronchial epithelium (HBE) cell lines [62].
This occurs through specific binding of piR-L-163 to the
phosphorylated form of the ERM (ezrin, radixin and moe-
sin) protein, which suggests a functional role of piRNAs in
lung tumorigenesis. Remarkably, this also reveals another
dimension of PIWI-independent functional roles of piR-
NAs in cancer.
Altered expression of piRNAs in cancers
Despite the number of total piRNAs encoded in the
human genome, only a small fraction is consistently
expressed in both non-malignant and tumor tissue [64].
Aberrant expression of the piRNA/PIWI complex and
its correlation with clinical features in malignant tissues
points to a role for piRNAs in cancer. However, this
role is uncertain as the function of piRNA in somatic
tissue is still being established.
A recent study revealed that piRNA expression patterns
in human somatic tissue are markedly different across tis-
sue types [64]. Different degrees of heterogeneity in ex-
pression patterns can be observed across tissues. For
example, when the expression profiles of non-malignant
tissue derived from breast, lung and stomach are com-
pared, we observe that breast tissue shows a highly corre-
lated pattern across samples from different individuals.
On the other hand, discrete clusters of samples can be ob-
served in lung and stomach tissue (Fig. 4). Additionally,
tissue-specific piRNA signatures are also evident. The
underlying cause for these differences are still unknown;
however, these results warrant further exploration to elu-
cidate whether these differences might be linked to tissue-
specific features.
The aberrant expression of a small number of piRNAs
has been identified in multiple myeloma (MM), breast,
lung, gastric and other cancers (Table 1, Fig. 5) [64].
However, findings in liver, pancreas, MM, and lung re-
main preliminary. As well, few studies have addressed
the functional role of piRNAs in cancer progression.
Breast cancer Deep sequencing and RT-PCR of breast
cancer tumours and matched normal tissue samples found
four significantly upregulated piRNAs: piR-4987, piR-
20365, piR-20485, piR-20582 [73]. Additionally, small
RNA sequencing from breast cancer cell lines and tumour
biopsies identified over 100 piRNAs expressed in breast
cancer, some of which were influenced by cell cycle pro-
gression and the oncosuppressive estrogen receptor β. Of
the 100 piRNAs identified, 30 were differentially expressed
between malignant and non-malignant mammary epithe-
lial cells. Eight piRNAs in particular were found to be sig-
nificantly differentially expressed between tumour and
matched non-malignant tissue: piR-34736, piR-36249,
piR-35407, piR-36318, piR-34377, piR-36743, piR-36026,
and piR-31106. It is noteworthy that these mapped to re-
gions involved in key biological processes involved in can-
cer. The expression of PIWIL1 and PIWIL4 and other key
players in the piRNA biogenesis pathway also suggest a
driver role for piRNAs in breast cancer [74]. Another
study implicated piR-932 in aberrant DNA methylation.
PIWIL2 was found to be significantly overexpressed in
breast cancer stem cells, inducing epithelial-to-
mesenchymal transition (EMT) following TGF-β1 treat-
ment, and PIWIL2 also formed a complex with one of
three significantly overexpressed piRNAs, piR-932. The
expression level of putative tumour suppressor Latexin
decreased as PIWIL2 expression increased due to pro-
moter region CpG island methylation. This suggests the
piR-932/PIWIL2 complex results in hypermethylation of
Latexin, which in turn promotes EMT [75]. Similarly, a
recent study found that piR-021285 is involved in methy-
lation at a number of known breast cancer-related genes.
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Fig. 4 piRNA expression pattern across human somatic, non-malignant tissues. a As an example of piRNA expression pattern heterogeneity across
human somatic tissues, a similarity matrix was constructed using rank-normalized piRNA expression levels from breast (red), lung (blue) and stomach
(turquoise) non-malignant human tissue. This data is derived from small RNA sequencing efforts from the The Cancer Genome Atlas (TCGA)
consortium and processed through a computational pipeline to detect piRNA expression. Briefly, sequencing reads with a higher fraction of
piRNAs (24–31 bp length) were mapped to the hg19/GRCh37 built. Aligned reads were subsequently quantified using specific piRNAs annotations,
which account for the genomic locations of piRNA-encoding loci. Sample clustering was performed using Pearson correlation, and the correlation
coefficient is color-coded from blue (low correlation) to red (high correlation). Noticeably, different degrees of overall correlation across samples from
the same tissue origin are observed. Samples derived from breast tissue are mostly clustered together, denoting a high degree of similarity of piRNA
expression patterns, while lung and stomach denotes subgroups. The molecular origin and physiological functions of these piRNA-defined subgroups
is not completely understood, although it has been shown that these subgroups are linked to specific clinical features in cancer patients. b A subset of
piRNAs is able to define a tissue-specific piRNA expression signature. In the figure, the top 10 over- and under-expressed piRNA on each tissue is compared
against others. The expression is significantly different, assessed by comparative marker selection tool, with false discovery-rate (FDR) corrected p-value≤
0.05. Top panel: breast vs. lung + stomach; middle panel: lung vs. breast + stomach; bottom panel: stomach vs. breast + lung
Table 1 Summary of altered piRNA expression in cancer
Cancer Type piRNA ID Alteration Detection method Ref.
Breast piR-4987 upregulated deep sequencing of matched tumour-normal





piR-34736 downregulated small RNAseq of cell lines and tumour biopsies









Breast (CD44+/CD24−) piR-932 upregulated piRNA microarray of tumour tissue [75]
Gastric piR-823 downregulated piRNA microarray of cell lines, validated via PCR [76]
piR-651a upregulated piRNA microarray of matched tumour-normal tissues,
validated via PCR
[77]
piR-59056 upregulated Small RNAseq of matched tumour and normal tissues [78]
piR-32105
piR-58099
Kidney piR-32051 upregulated Small RNAseq of tumour tissue, validated via PCR [79]
piR-39894
piR-43607
piR-57125 downregulated in non-metastatic vs normal;
downregulated in metastatic vs non-metastatic
piRNA microarray of matched tumour-normal tissues,
validated via PCR
[80]
piR-38756 downregulated in non-metastatic vs normal;
upregulated in metastatic vs non-metastatic
piR-30924
Liver piR-Hep1 upregulated deep sequencing of cell lines, validated in matched
tumour-normal tissues via PCR
[81]
Pancreas piR-017061 downregulated small RNAseq of tumour and normal tissue [83]
Multiple Myeloma piR-823 upregulated piRNA microarray of tumour and normal tissue,
validated via PCR
[84]
Lung piR-L-163 downregulated small RNAseq of NSCLC cell lines [62]
aalso upregulated in colon, lung, and breast cancer tissue and hepatic carcinoma, mesothelioma, cervical, breast, and lung cancer cell lines




Fig. 5 (See legend on next page.)
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In particular, the single nucleotide polymorphism (SNP)
rs1326306-containing piR-021285 was found to increase
mRNA expression of ARHGAP11A and invasiveness in an
in vitro cell line model [71].
Gastric cancer piR-823 was found to be significantly
downregulated compared to matched non-malignant sam-
ples in four patients. Cancer cell growth was inhibited by
overexpression of piR-823 in vitro, and tumour growth in
a xenograft model was significantly suppressed, both in a
dose-dependent manner. As there was no association with
clinicopathological features of patients, its oncogenic role
in gastric cancer has been suggested to be during pre-
cancerous stages of tumorigenesis [76]. Aberrant expres-
sion of another piRNA, piR-651, was identified in gastric
cancer. Significant overexpression of piR-651 was found in
4 paired tumour and non-malignant samples by piRNA
microarray and confirmed by PCR in a larger cohort of
tumour and non-malignant tissues. piR-651 inhibition in
gastric cancer cell lines suppressed growth in a dose
dependent manner and resulted in cell cycle arrest at the
G2/M stage [77]. Upregulation of piR-651 was also ob-
served in colon, lung, and breast cancer tissues as well as
hepatic carcinoma, mesothelioma, cervical, breast, and
lung cancer cell lines suggesting an oncogenic role across
cancer types [77]. More recently, small RNA sequencing
data from 320 gastric cancer and 38 non-malignant tis-
sue samples identified the expression of 312 piRNAs, of
which half were significantly differentially expressed in
tumour tissues compared to non-malignant tissues.
Some exhibited either gastric cancer or non-malignant
stomach tissue specific expression; most were overex-
pressed in tumour tissue, including piR-59056, piR-
32105, and piR-58099 [78].
Kidney cancer In kidney cancer, deep sequencing of 24
samples found 19 piRNAs to be differentially expressed
between clear cell renal cell carcinoma (ccRCC) and be-
nign kidney tissue, and 46 piRNAs to be differentially
expressed between localized and metastatic ccRCC. Of
those piRNAs aberrantly expressed in metastatic ccRCC,
three upregulated piRNAs, piR-32051, piR-39894, piR-
43607, are from the same piRNA cluster on chromo-
some 17, and were also overexpressed in embryonic and
neoplastic kidney cell lines compared to benign [79].
Validation in an external cohort also found them to be as-
sociated with ccRCC metastasis as well as high tumour
stage and patient survival [79]. Another study on ccRCC,
aimed at identifying prognostic markers, identified 235
upregulated and 369 downregulated piRNAs in malignant
tissue by piRNA microarray from 106 patient samples.
RT-qPCR analysis of confirmed decreased expression of
piR-38756, piR-57125, and piR-30924 in non-metastatic
primary tumours compared to normal tissue. However,
when comparing metastatic primary tumours and bone
metastases to non-metastatic primary tumours, piR-57125
was downregulated and piR-38756 and piR-30924 were
upregulated [80].
Liver cancer A novel piRNA, piR-Hep1, was identified
through deep sequencing and found to be upregulated in
hepatocellular carcinoma (HCC) compared to adjacent
non-malignant liver tissue. PIWIL2 expression, but not
PIWIL4 expression, positively correlated with expression
of piR-Hep1 in HCC, suggesting PIWIL2 complexes with
piR-Hep1 to promote tumorigenesis. piR-Hep1 silencing
inhibited cell viability, motility, and invasiveness and
also reduced levels of active phosphorylated AKT [81],
which has been previously shown to be activated by
PIWIL2 inhibiting apoptosis through the Stat3/Bcl-XL
pathway [82].
Pancreatic cancer Next generation sequencing revealed
one piRNA, piR-017061, located within HBII-296A
snoRNA, to be significantly downregulated in pancre-
atic ductal adenocarcinoma (PDAC) compared to non-
malignant pancreatic control tissues [83].
Multiple myeloma In contrast to gastric cancer, in
which it was downregulated, piR-823 was found to be
upregulated in MM patients and MM cell lines; overex-
pression correlated with worse prognosis. In vivo, piR-
823 inhibition resulted in differential expression and
phosphorylation of key apoptotic, proliferative, and cell
cycle genes and also suppressed pro-angiogenic activity.
It was also shown to be a direct regulator of DNA meth-
yltransferases 3A and 3B. The inhibition of piR-823 de-
creased global methylation in MM cells, suggesting that
(See figure on previous page.)
Fig. 5 Distribution of piRNAs expression in human cancer genome. Circular representation of the human genome (chromosomes 1–22, X and Y).
The distribution of piRNA expression in non-malignant (outward lines) and tumors (inward lines) from breast (red), lung (blue and green from
samples derived from adenocarcinomas and squamous cell carcinomas, respectively) and stomach (turquoise) is shown in a circular representation of
the human genome. Clusters of highly expressed piRNAs are evident in chromosomes 2, 5, 10, 13, 21 and X. Although expression of some piRNAs is
common across tissues (a), some of them show tissue-specific features (b). Moreover, differences between tumour and normal tissue are observable
(c). The outer grey circle is a representation of the human mitochondrial genome. Blue bars depict the location of of these piRNA species in the
mitochondrial DNA (note: the height of the blue bars does not represent expression levels of the piRNA species, since data for some of the original
studies is not still publically available. Inner black and red labels represent previously known piRNA sequences and piRNA-like species that map to the
mitochondrial genome [59, 61] (d)
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aberrant DNA methylation targeting tumour suppressor
genes promotes tumorigenesis. Decreased tumour size
with piR-823 inhibition in xenograft mouse models fur-
ther supports its role in tumour growth [84].
Lung cancer A recent lung cancer study identified 555
piRNAs expressed in 8 non-small cell lung cancer
(NSCLC) and 3 human bronchial epithelial cell (HBEC)
lines, of which over half were novel piRNA-like (piRNA-
L) sncRNAs [62]. These piRNAs were found to be differ-
entially expressed between NSCLC and HBEC lines, and
also among adenocarcinoma and squamous cell carcin-
oma subtypes. The most commonly downregulated
piRNA in NSCLC was piR-L-163, located in intron 10 of
the LAMC2 gene. piR-L-163 was implicated in cell cycle
regulation, as inhibition enhanced cell viability and prolif-
eration and accelerated DNA synthesis and G2-M accu-
mulation compared to the control. Blocking piR-L-163
also significantly increased invasion and migration of
HBECs. This piRNA-L localized to the cytoplasm and was
shown to bind to phosphorylated ERM proteins. piR-L-
163 directly regulates protein function as this binding
interaction was essential for p-moesin to bind F-actin and
EBP50 [62].
Aberrant expression of piRNA and piRNA pathway
components are observed across cancer types and have
been shown to influence hallmarks of cancer. While differ-
ences in piRNA expression are capable of distinguishing
tissues types -possibly indicating a tissue-specific role for
these piRNAs- some piRNAs are consistently highly
expressed across all tissue types examined, which could
suggest a conserved general function for these piRNAs in
somatic tissues [64]. Though functional studies are still
preliminary, it is clear that the mechanisms through which
piRNA contribute to cancer are varied owing to the di-
verse functionality of piRNAs in germline, and now som-
atic, tissues.
Diagnostic and prognostic utility of piRNAs
As diagnostic and therapeutic procedures move from bi-
opsies towards less invasive methods, piRNAs represent
an attractive biomarker candidate. Much of this research
has centred around circulating nucleic acids in plasma.
As with miRNA, piRNAs remain largely undegraded in
circulation and have the ability to resist a wide range of
incubation and storage conditions regularly used in the
laboratory [85, 86]. Indeed, a recent study of piRNAs in
gastric cancer found that, when compared to an existing
miRNA-based biomarker detection system, piRNAs pro-
vided higher sensitivity and specificity [87]. One caveat
with piRNA-based biomarkers is that, as with miRNA,
normalization across subjects has proved challenging;
however, a recent study has described the potential of
salivary piRNA being used as an alternative to or in con-
junction with plasma-based systems [88]. In particular,
the high abundance of piRNA in saliva as well as high
concordancy levels between subjects warrants further
exploration. Differential or cancer-specific piRNA ex-
pression has been reported across a number of tumour
types (Table 2). In gastric cancer, a three-piRNA signa-
ture of piR-59056, piR-54878, and piR-62701 was able to
effectively separate patients by risk of recurrence. A
similar association with recurrence-free survival was ob-
served in colon cancer [78]. Both piR-823 and piR-651
Table 2 piRNAs associated with clinical parameters in cancer
Cancer Type piRNA ID Clinical Parameter Reference
Gastric piR-59056 Recurrence-free survival (3 piRNA signature) [78]
piR-54878
piR-62701
piR-651 TNM stage [77]
piR-651 T stage, metastasis, gastric vs. signet ring cell (2 piRNA signature) [87]
piR-823
Colon piR-59056 Recurrence-free survival (3 piRNA signature) [78]
piR-54878
piR-62701
Breast piR-4987 Lymph node positivity [73]
Kidney piR-30924 Overall survival, tumour progression (3 piRNA signature) [80]
piR-57125
piR-38756
piR-32051 Cancer-specific survival, stage, metastasis (3 piRNA signature) [79]
piR-39894
piR-43607
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have been investigated as potential plasma biomarkers
for gastric cancer. Compared to healthy controls, both
were found at significantly lower levels in peripheral
blood in cancer patients. Additionally, piR-823 and piR-
651 levels in peripheral blood were found to associate
with tumour stage and distant metastasis, and were also
able to effectively distinguish gastric adenocarcinoma
from signet ring cell carcinoma [87]. In another study,
tumour-derived levels of piR-651 were found to associate
with TNM stage and poorly differentiated tumours [77].
Though the role of piRNAs in breast cancer is less
well-described compared to that in gastric cancer, recent
studies have demonstrated that they too can be effect-
ively harnessed for clinical purposes. As with in gastric
cancer, a high proportion of all piRNAs expressed in
breast cancer map to protein coding regions in the gen-
ome, primarily within intragenic regions [74]. A study of
54 breast ductal carcinoma tissue samples identified six
piRNAs that were differentially expressed - among them,
piR-4987 upregulation was associated with lymph node
metastasis [73]. Similarly, two recent studies done in
clear cell renal carcinoma implicated piRNAs as being of
important prognostic value: Busch et al. identified three
piRNAs significantly associated with overall survival and
tumour progression, two of which were able to serve as
independent prognostic markers [80], and Li et al. de-
scribed a three-piRNA signature located on chromosome
17 that was shown to be associated with metastasis, stage,
and cancer-specific survival [79]. These advances highlight
the potential of piRNA-based prognostic markers across a
variety of tumour types.
Beyond a biomarker role, a recent study demonstrated
the potential for piRNA as a therapeutic tool. In a
mouse model, it was found that artificial piRNA could
be generated through the expression of sense and anti-
sense transcripts, which was sufficient to induce epigen-
etic silencing of the target gene [89]. This research
highlights the potential of piRNAs as clinical biomarkers
as well as reinforces the need to further understand
piRNA mechanisms of action for potential therapeutic
exploitation.
Conclusions and future directions
The advent of high-throughput sequencing technolo-
gies has effectively enabled the delineation of the cru-
cial roles of non-coding RNA in pathogenesis as well as
in normal cellular biology. In particular, piRNAs have
emerged as a highly promising area of study given their
gene regulatory function both in the nucleus and in the
cytoplasm. Further study into the distinct splicing
mechanisms involved in piRNA production is also war-
ranted to determine whether there is a link between
method of production and function.
While expression patterns of other small non-coding
RNAs such as miRNAs have been extensively studied,
malignant and non-malignant piRNA expression pat-
terns are largely uncharted. Aberrant piRNA expression
has now been extensively described across a variety of
tumour types, though further research is needed to elu-
cidate the specific oncogenic or tumour-suppressing
mechanisms. Moreover, the expression patterns are spe-
cific to malignancies, and subgroup-specific piRNA ex-
pression patterns from tumours of the same organ exist
and correlate with key clinical features relevant to each
tumour type.
The study of distinct alterations affecting piRNA ex-
pression and their functional consequences in the devel-
opment of human cancer is advancing rapidly. While we
can still apply lessons learned from the miRNA field, the
evidence points towards an additional spectrum of func-
tions potentially affected by piRNAs. More importantly,
these functions can be complementary to those per-
formed by other small RNA (e.g. DNA-level coupled
with RNA-level regulation of gene expression, performed
by piRNAs and miRNAs, respectively). If this phenomenon
exists, are functionally-related genes subject to this type of
“dual” regulation?. It is also very relevant to investigate the
physiological roles of piRNAs in normal somatic tissue. By
understanding physiological function, it would be possible
to decipher molecular functions potentially affected when
piRNA expression is deregulated during cancer develop-
ment. This knowledge will be also useful to refine thera-
peutic applications of piRNA.
The interaction between piRNA and PIWI proteins is
well established and characterized in a vast amount of
organisms. While these interactions may impact tumori-
genic functions (supported by the fact that PIWI pro-
teins are deregulated in a variety of cancers), it is also
intriguing to decipher other PIWI-independent interac-
tions of piRNAs. The discovery of such novel interac-
tions may lead to the discovery of new mechanisms of
regulation of malignancy-associated pathways affected
by altered piRNA expression.
The development of piRNAs as therapeutic tools also
raises question and challenges. Since recent evidence
points to piRNAs as potential tools to modulate the activity
of tumor suppressor genes (e.g. TRAIL in breast cancer), it
is important to investigate what other tumor suppressor
activities can be enhanced by piRNA expression (either
natural or ectopic). This is particularly relevant due to the
tissue specificity of both piRNA expression and tumor sup-
pressor activity. Further study of the mechanistic role of
piRNA in tumour progression across a wider spectrum of
tissue types, along with increased investigation into base-
line functions of piRNA in human somatic tissue, will
surely yield novel insights in this fast-growing field of non-
coding RNA in cancer biology.
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